Naunyn-Schmiedeberg's archives of pharmacology
Icariside II sensitizes osteosarcoma to doxorubicin through the lincROR/Wnt/β-catenin signaling regulatory axis.
Shu-Ting Zhou, Zhi-Peng Li, Yong-Xin Mai, Yu-Yan Wang, Feng-Xiang Pang, Jin-Fang Zhang, Xian-Lin Wu
Published: 202510.1007/s00210-025-04760-1
Abstract
Doxorubicin (DOX) is a widely used chemotherapeutic drug for human osteosarcoma (OS). However, the acquired resistance of OS to DOX is a common phenomenon among OS patients, which seriously constrains its therapeutic efficacy in clinical practice. Im…
Preview only. Read the full abstract at the source